$DMAC
DiaMedica Therapeutics Inc.

2021 Q4 Form 10-K Financial Statement

#000143774922006163 Filed on March 14, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.375M $1.084M $4.881M
YoY Change 19.57% -4.91% 11.18%
% of Gross Profit
Research & Development $1.871M $2.332M $8.765M
YoY Change -40.03% 8.06% 6.83%
% of Gross Profit
Depreciation & Amortization $6.000K $6.000K $24.00K
YoY Change -40.0% 14.29%
% of Gross Profit
Operating Expenses $3.246M $2.332M $13.65M
YoY Change -23.98% 8.06% 7.46%
Operating Profit -$3.416M -$13.65M
YoY Change 2.92% 7.46%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.000K -$27.00K $82.00K
YoY Change -91.25% -121.09% -81.11%
Pretax Income -$3.239M -$3.443M -$13.56M
YoY Change -22.7% 7.9% 10.59%
Income Tax $7.000K $7.000K $28.00K
% Of Pretax Income
Net Earnings -$3.246M -$3.450M -$13.59M
YoY Change -22.71% 8.05% 10.58%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18 -$0.65
Diluted Earnings Per Share -$122.5K -$181.2K -$654.3K
COMMON SHARES
Basic Shares Outstanding 26.44M 18.79M 20.77M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.81M $48.12M $45.11M
YoY Change 42.68% 57.27% 63.98%
Cash & Equivalents $4.707M $16.22M
Short-Term Investments $45.10M $31.90M $40.41M
Other Short-Term Assets $197.0K $336.0K $197.0K
YoY Change 181.43% 124.0% 181.43%
Inventory
Prepaid Expenses $84.00K
Receivables $130.0K $104.0K $130.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $45.44M $48.54M $45.44M
YoY Change 62.74% 56.04% 62.75%
LONG-TERM ASSETS
Property, Plant & Equipment $70.00K $70.00K $112.0K
YoY Change -5.41% 40.0% -34.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $112.0K $127.0K $112.0K
YoY Change -35.63% -22.56% -37.78%
TOTAL ASSETS
Total Short-Term Assets $45.44M $48.54M $45.44M
Total Long-Term Assets $112.0K $127.0K $112.0K
Total Assets $45.55M $48.66M $45.55M
YoY Change 62.13% 55.63% 62.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $509.0K $699.0K $509.0K
YoY Change -53.69% -2.92% -53.73%
Accrued Expenses $966.0K $861.0K $1.011M
YoY Change 11.81% 30.85% 9.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000K $4.000K $4.000K
YoY Change -60.0% -60.0% -60.0%
Total Short-Term Liabilities $1.524M $1.624M $1.524M
YoY Change -24.85% 12.54% -24.93%
LONG-TERM LIABILITIES
Long-Term Debt $3.000K $4.000K $3.000K
YoY Change -70.0% -60.0% -70.0%
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Long-Term Liabilities $3.000K $4.000K $3.000K
YoY Change -94.34% -94.2% -95.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.524M $1.624M $1.524M
Total Long-Term Liabilities $3.000K $4.000K $3.000K
Total Liabilities $1.527M $1.628M $1.527M
YoY Change -26.62% 7.67% -26.59%
SHAREHOLDERS EQUITY
Retained Earnings -$82.50M -$79.30M
YoY Change 19.72% 22.55%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.02M $47.00M $44.02M
YoY Change
Total Liabilities & Shareholders Equity $45.55M $48.66M $45.55M
YoY Change 62.13% 55.63% 62.1%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021
OPERATING ACTIVITIES
Net Income -$3.246M -$3.450M -$13.59M
YoY Change -22.71% 8.05% 10.58%
Depreciation, Depletion And Amortization $6.000K $6.000K $24.00K
YoY Change -40.0% 14.29%
Cash From Operating Activities -$2.804M -$3.046M -$12.30M
YoY Change -7.15% 29.62% 33.91%
INVESTING ACTIVITIES
Capital Expenditures -$7.000K -$2.000K $22.00K
YoY Change -86.0% -53.19%
Acquisitions
YoY Change
Other Investing Activities -$8.682M -$12.83M -$20.52M
YoY Change -1322.82% -8.39% 27.5%
Cash From Investing Activities -$8.689M -$12.83M -$20.54M
YoY Change -1396.87% -8.37% 27.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.00M $29.85M
YoY Change 30.43% 3.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.00K 29.87M $30.09M
YoY Change -36.67% 41.01% 4.31%
NET CHANGE
Cash From Operating Activities -2.804M -3.046M -$12.30M
Cash From Investing Activities -8.689M -12.83M -$20.54M
Cash From Financing Activities -19.00K 29.87M $30.09M
Net Change In Cash -11.51M 13.99M -$2.702M
YoY Change 383.7% 189.67% -176.63%
FREE CASH FLOW
Cash From Operating Activities -$2.804M -$3.046M -$12.30M
Capital Expenditures -$7.000K -$2.000K $22.00K
Free Cash Flow -$2.797M -$3.044M -$12.32M
YoY Change -5.82% 29.53% 33.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
113000 USD
CY2021 dei Auditor Location
AuditorLocation
Minneapolis, MN
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26443067
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26443067
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18746157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18746157
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
151000 USD
CY2021 dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4707000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7409000 USD
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
40405000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20098000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
130000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000 USD
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
10000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
84000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
64000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45439000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27921000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 USD
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
112000 USD
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
174000 USD
CY2021Q4 us-gaap Assets
Assets
45551000 USD
CY2020Q4 us-gaap Assets
Assets
28095000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
509000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1099000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
966000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
864000 USD
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1524000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000 USD
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46000 USD
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
53000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126576000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94925000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-51000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82501000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68909000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44024000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45551000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28095000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8765000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8205000 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4881000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4494000 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
13646000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
12699000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-13646000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-12699000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
82000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
229000 USD
CY2021 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
0 USD
CY2020 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
205000 USD
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
82000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
434000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13564000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12265000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13592000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12292000 USD
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13641000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12296000 USD
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20773399
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15680320
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28805000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45000 USD
CY2020 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1843000 USD
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12292000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29849000 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 USD
CY2021 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1558000 USD
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13592000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44024000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13592000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12292000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1558000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1843000 USD
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-161000 USD
CY2020 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
4000 USD
CY2021 dmac Noncash Lease Expense
NoncashLeaseExpense
58000 USD
CY2020 dmac Noncash Lease Expense
NoncashLeaseExpense
52000 USD
CY2021 us-gaap Depreciation
Depreciation
24000 USD
CY2020 us-gaap Depreciation
Depreciation
21000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-210000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-483000 USD
CY2021 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
103000 USD
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-78000 USD
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
20000 USD
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
17000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-590000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
917000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
42000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-266000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12252000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9185000 USD
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
69813000 USD
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39746000 USD
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
49296000 USD
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
23643000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47000 USD
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 USD
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
16000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20537000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16134000 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29849000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28805000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000 USD
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6000 USD
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30087000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28845000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2702000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3526000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4707000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
28000 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
36000 USD
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2229259
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82500000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13600000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12300000 USD
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
45100000 USD
CY2021Q4 dmac Working Capital
WorkingCapital
43900000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44000000.0 USD
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
29800000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of credit risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <em style="font: inherit;">two</em> financial institutions. These balances generally exceed federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1701801
CY2020 dmac Research Grant Recognized Research Activities Performed
ResearchGrantRecognizedResearchActivitiesPerformed
205000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13592000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-12292000 USD
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20773399
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15680320
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
130000 USD
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
34000 USD
CY2021Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
0 USD
CY2020Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000 USD
CY2021Q4 us-gaap Other Receivables
OtherReceivables
0 USD
CY2020Q4 us-gaap Other Receivables
OtherReceivables
17000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
130000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000 USD
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
113000 USD
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
10000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
137000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
57000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 USD
CY2021 us-gaap Depreciation
Depreciation
24000 USD
CY2020 us-gaap Depreciation
Depreciation
21000 USD
CY2021 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
17000 USD
CY2020 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
23000 USD
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
509000 USD
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1099000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
484000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
483000 USD
CY2021Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
191000 USD
CY2020Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
360000 USD
CY2021Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
284000 USD
CY2020Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
13000 USD
CY2021Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000 USD
CY2020Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
8000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1475000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1963000 USD
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09 pure
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
65000 USD
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
66000 USD
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
56000 USD
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
53000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
46000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
45000 USD
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7653060
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.92
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000.0 USD
CY2021Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
29800000 USD
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 USD
CY2021 dmac Stock Issued During Period Shares Settlement Of Deferred Stock Units
StockIssuedDuringPeriodSharesSettlementOfDeferredStockUnits
3850
CY2020Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000
CY2020Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.00
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000000.0 USD
CY2020Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
21100000 USD
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.00
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000 USD
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000 USD
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14283
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
45161 USD
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3736910
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6000 USD
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1558000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1843000 USD
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
390826
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.49
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
638008
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.16
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
347110
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.26
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
70000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.70
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
611724
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.21
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1896600
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.25
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1284876
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
45000 USD
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1800000 USD
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
132000 USD
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
41000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04 pure
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
87000 USD
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
62000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17596000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14321000 USD
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
817000 USD
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
817000 USD
CY2021Q4 dmac Deferred Tax Assets Property Share Issue Costs
DeferredTaxAssetsPropertyShareIssueCosts
608000 USD
CY2020Q4 dmac Deferred Tax Assets Property Share Issue Costs
DeferredTaxAssetsPropertyShareIssueCosts
837000 USD
CY2021Q4 dmac Deferred Tax Assets Property Patents And Other
DeferredTaxAssetsPropertyPatentsAndOther
309000 USD
CY2020Q4 dmac Deferred Tax Assets Property Patents And Other
DeferredTaxAssetsPropertyPatentsAndOther
300000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
76000 USD
CY2021 dmac Income Tax Rate Reconciliation Share Issuance Costs Amount
IncomeTaxRateReconciliationShareIssuanceCostsAmount
-41000 USD
CY2020 dmac Income Tax Rate Reconciliation Share Issuance Costs Amount
IncomeTaxRateReconciliationShareIssuanceCostsAmount
-728000 USD
CY2021 dmac Effective Income Tax Rate Reconciliation Australian Research And Development Incentive
EffectiveIncomeTaxRateReconciliationAustralianResearchAndDevelopmentIncentive
2000 USD
CY2020 dmac Effective Income Tax Rate Reconciliation Australian Research And Development Incentive
EffectiveIncomeTaxRateReconciliationAustralianResearchAndDevelopmentIncentive
-102000 USD
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
42000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
13000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
14000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
19393000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
16267000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19393000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16267000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.270 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.270 pure
CY2021 dmac Effective Income Tax Rate Reconciliation Income Tax Recovery Amount
EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount
-3656000 USD
CY2020 dmac Effective Income Tax Rate Reconciliation Income Tax Recovery Amount
EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount
-3274000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
421000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
498000 USD
CY2021 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
134000 USD
CY2020 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
84000 USD
CY2020 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
15000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3126000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3534000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000 USD

Files In Submission

Name View Source Status
0001437749-22-006163-index-headers.html Edgar Link pending
0001437749-22-006163-index.html Edgar Link pending
0001437749-22-006163.txt Edgar Link pending
0001437749-22-006163-xbrl.zip Edgar Link pending
a10.jpg Edgar Link pending
a2.jpg Edgar Link pending
a3.jpg Edgar Link pending
a4.jpg Edgar Link pending
a5.jpg Edgar Link pending
dmac-20211231.xsd Edgar Link pending
dmac-20211231_cal.xml Edgar Link unprocessable
dmac-20211231_def.xml Edgar Link unprocessable
dmac-20211231_lab.xml Edgar Link unprocessable
dmac-20211231_pre.xml Edgar Link unprocessable
dmtp20211231_10k.htm Edgar Link pending
dmtp20211231_10k_htm.xml Edgar Link completed
ex_343867.htm Edgar Link pending
ex_343868.htm Edgar Link pending
ex_343869.htm Edgar Link pending
ex_343870.htm Edgar Link pending
ex_343871.htm Edgar Link pending
ex_343872.htm Edgar Link pending
ex_343873.htm Edgar Link pending
ex_344771.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img01.jpg Edgar Link pending
img02.jpg Edgar Link pending
logo01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending